Efficacy and safety of dimeticones in the treatment of epidermal parasitic skin diseases with special emphasis on tungiasis: an evidence-based critical review

Background: Scabies is one of the most common skin diseases in our country. It is caused by the mite Sarcoptes scabiei var hominis, which is an ecto-parasite infesting the epidermis. Scabies is highly contagious. Prevalence is high in congested or densely populated areas. Individuals with close contact with an affected person should be treated with scabicidal which is available in both oral and topical formulations. The only oral but highly effective scabicidal known to date is Ivermectin. Amongst topical preparations, Permethrin 5 % cream is the treatment of choice. Objective: To evaluate the efficacy & safety of oral Ivermectin compared to topical Permethrin in the treatment of scabies. Methodology: This prospective, non-randomized study was conducted at the out-patient department of Dermatology and Venereology of Shaheed Suhrawardy Medical College & Hospital over a period of 6 months, from August 2016 to January 2017. The study population consisted of one hundred patients having scabies, enrolled according to inclusion criteria. They were divided into two groups. group A was subjected to oral Ivermectin and the group B to Permethrin 5% cream. Patients were followed up on day 7 and 14 for assessment of efficacy and safety. Result: The mean scoring with SD in group A (Ivermectin) and group B (Permethrin) were 8.26 ± 2.22 and 7.59 ± 2.01 respectively at the time of observation. The difference between the mean score of the two group is not significant (p=0.117) the mean scoring with SD in group A and group B were 4.54 ± 2.05 and 1.64 ± 1.84 respectively at 7thdays. The difference between the mean score of the two group is significant (p<0.001). The mean scoring with SD in group A and group B were 2.68± 2.35 and .36± 1.10 respectively at 14th day difference between the mean score of the group is significant (p<0.001). Conclusion: Topical application of permethrin 5% cream is more effective and safer than oral Ivermectin in the treatment of scabies. TAJ 2020; 33(1): 41-47

Download Full-text

153 Efficacy and safety of acyclovir as prevention of varicella dissemination in immunocompromised children: an evidence-based case report

10.1136/bmjpo-2021-rcpch.87 ◽

2021 ◽

Author(s):

Assyifa Gita Firdaus ◽

Nina Dwi Putri ◽

Mulya Rahma Karyanti

Keyword(s):

Case Report ◽

Evidence Based ◽

Efficacy And Safety

Download Full-text

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Toxins ◽

10.3390/toxins13020120 ◽

2021 ◽

Vol 13 (2) ◽

pp. 120

Author(s):

Emanuela Martina ◽

Federico Diotallevi ◽

Giulia Radi ◽

Anna Campanati ◽

Annamaria Offidani

Keyword(s):

Systematic Review ◽

Skin Diseases ◽

Meta Analysis ◽

Published Data ◽

Efficacy And Safety ◽

Botulinum Toxins ◽

Epidermolysis Bullosa Simplex ◽

Off Label ◽

Facial Erythema ◽

Notalgia Paresthetica

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

Download Full-text

A Critical Review of the Efficacy and Safety of Inclisiran

American Journal of Cardiovascular Drugs ◽

10.1007/s40256-021-00477-7 ◽

2021 ◽

Author(s):

Jennifer Hardy ◽

Stephanie Niman ◽

Edward Pereira ◽

Todd Lewis ◽

Jessica Reid ◽

...

Keyword(s):

Critical Review ◽

Efficacy And Safety

Download Full-text

Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature

Archivio Italiano di Urologia e Andrologia ◽

10.4081/aiua.2019.4.205 ◽

2020 ◽

Vol 91 (4) ◽

pp. 205-210

Author(s):

Gian Maria Busetto ◽

Francesco Del Giudice ◽

Daniele D'Agostino ◽

Daniele Romagnoli ◽

Andrea Minervini ◽

...

Keyword(s):

Clinical Trials ◽

Benign Prostatic Hyperplasia ◽

Adverse Events ◽

Clinical Efficacy ◽

Critical Review ◽

Reductase Inhibitor ◽

Prostate Volume ◽

Prostatic Hyperplasia ◽

Urinary Flow ◽

Efficacy And Safety

Background: Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be considered as a gold standard intervention for medical management of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). On the other hand, 5-ARI monotherapy and in particular Finasteride alone is currently getting focus of attention especially due to lack of systematic reviews investigating efficacy outcomes and/or adverse events associated. Objectives: Aim of the present critical review was to analyze current knowledge of clinical efficacy and incidence of adverse events associated with 5-ARI treatment for LUTS/BPH. Materials and methods: A systematic review of clinical trials of the literature of the past 20 years was performed using database from PubMed, Cochrane Collaboration and Embase. A total of 8821 patients were included in this study and inclusion criteria for studies selection were: data from randomized clinical trials (RCTs) focusing their attention on the clinical role of Finasteride monotherapy for symptomatic BPH. Parameters of research included prostate specific antigen (PSA), prostate volume (PV), International Prostate Symptom Score (IPPS), postvoid residual urine (PVR), voiding symptoms of IPSS (voiding IPSS), maximum urinary flow rate (Qmax), and adverse events (AEs). Results: Overall 12 original articles were included and critically evaluated. Sample sizes of patient actively treated with finasteride varied from 13 to 1524 cases analyzed in a single study. Follow-up after treatments ranged from 3 to 54 months. The effect of finasteride in reducing prostate volume (PV) was moderate (standardized mean difference (SMD) effect between 0.5 to 0.8 for all trials evaluable) while the effect on IPSS score and Qmax was considered significant (SMD in the 0.2 to 0.5 variation range). No severe AEs and/or psychiatric disorders were retrieved among the studies. Sexual health dysfunctions were significantly influenced by finasteride therapy when compared with placebo treated patients. Conclusions: Although significant clinical benefits of finasteride monotherapy were demonstrated, the effective size of the available reports included in the analysis is limited. Additional head-to-head studies would be needed to re-evaluate clinical efficacy and safety of 5-ARI in combination or not with alpha blockers.

Download Full-text

Evidence-Based Hypnotherapy for Asthma:A Critical Review

International Journal of Clinical and Experimental Hypnosis ◽

10.1080/00207140601177947 ◽

2007 ◽

Vol 55 (2) ◽

pp. 220-249 ◽

Cited By ~ 19

Author(s):

Daniel Brown

Keyword(s):

Critical Review ◽

Evidence Based

Download Full-text

Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update

Medicina ◽

10.3390/medicina57010058 ◽

2021 ◽

Vol 57 (1) ◽

pp. 58

Author(s):

Arrigo F. G. Cicero ◽

Federica Fogacci ◽

Masanari Kuwabara ◽

Claudio Borghi

Keyword(s):

Clinical Trials ◽

Uric Acid ◽

Clinical Research ◽

Safety Profile ◽

Therapeutic Strategies ◽

Evidence Based ◽

Acute Management ◽

Efficacy And Safety ◽

Uricosuric Agents ◽

Xanthine Oxidase Inhibitors

This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that further well-designed clinical research is needed to deepen their efficacy and safety profile.

Download Full-text

The Efficacy and Safety of Dual-Frequency Ultrasound for Improving Skin Hydration and Erythema in Patients with Rosacea and Acne

Journal of Clinical Medicine ◽

10.3390/jcm10040834 ◽

2021 ◽

Vol 10 (4) ◽

pp. 834

Author(s):

Young Jae Kim ◽

Ik Jun Moon ◽

Hae Woong Lee ◽

Chong Hyun Won ◽

Sung Eun Chang ◽

...

Keyword(s):

Skin Diseases ◽

Skin Barrier ◽

Skin Hydration ◽

Efficacy And Safety ◽

Dual Frequency ◽

Barrier Dysfunction ◽

Inflammatory Skin Diseases ◽

Facial Erythema ◽

Frequency Ultrasound

Inflammatory skin diseases, such as rosacea and acne, are major causes of facial erythema and accompanying skin barrier dysfunction. Several methods to restore the impaired skin barrier and improve facial erythema, such as medication, radiofrequency, laser, and ultrasound therapy were attempted. This study evaluated the efficacy and safety of dual-frequency ultrasound with impulse mode, for improving skin hydration and erythema in Asian subjects with rosacea and acne. Twenty-six subjects with facial erythema received an ultrasound treatment once per week, for 4 weeks, over both cheeks. The erythema index and transepidermal water loss (TEWL) were measured at each visit. Clinicians assessed the erythema improvement and patients evaluated their satisfaction level. The average decrease in TEWL and erythema index at 6 weeks was 5.37 ± 13.22 g·h−1·m−2 (p = 0.020) and 39.73 ± 44.21 (p = 0.010), respectively. The clinician’s erythema assessment and the subject satisfaction questionnaire score significantly improved at final follow-up (p < 0.001; p = 0.003, respectively). No serious adverse effects were observed during the treatment and follow-up periods. The dual-frequency ultrasound with impulse mode appears to be effective and safe for improving skin hydration and erythema in patients with rosacea and acne.

Download Full-text